BostonGene Earns Gold and Silver Stevie Awards for Cancer Care Innovation
BostonGene, a leader in artificial intelligence–driven molecular profiling, received a Gold Stevie and two Silver Stevies for its work advancing cancer care. The honors were presented at the annual Stevie Awards for Technology Excellence, often called the "Olympics of technology." Together, the awards recognize how BostonGene applies AI to help personalize treatment decisions for people facing cancer.
Honors for Innovation and Excellence
The Stevie Awards spotlight standout achievements across industries where innovation makes the difference. BostonGene’s recognition reflects its impact on tailoring cancer therapy with advanced technology. The awards also honor the teams and individuals whose daily work drives breakthroughs in healthcare technology.
Gold Stevie: AI-Based Digital Pathology Platform
BostonGene’s AI-based digital pathology platform earned the Gold Stevie for its approach to analyzing tumor tissue. The technology reduces human error and standardizes diagnostic procedures, which makes results more consistent. More accurate diagnoses mean critical biomarkers are identified with greater reliability, enabling more personalized treatment paths and raising the standard of care.
Silver Stevie: Immune System Profiling Platform
One Silver Stevie recognized BostonGene’s immune system profiling platform. This solution builds a unique classification and scoring system that links systemic immunity with how patients respond to different cancer treatments. That connection adds a new layer to personalized care and supports more tailored therapeutic strategies.
Silver Stevie: Tumor Portrait™ Test
The Tumor Portrait™ test received a second Silver Stevie. The test identifies biomarkers and actionable mutations and examines properties of the immune microenvironment. By merging DNA and RNA findings into one comprehensive report, it equips clinicians to select the most effective treatment options, with a clear impact on clinical outcomes.
BostonGene’s Commitment to Advancing Cancer Medicine
Andrew Feinberg, President and CEO of BostonGene, expressed pride in the recognition and noted that the awards reinforce the company’s commitment to innovating cancer care. He emphasized the goal of transforming drug development and accelerating the delivery of lifesaving therapies through AI-enhanced clinical trial designs.
About BostonGene Corporation
BostonGene is a biotechnology company that unites technology and biology to advance personalized cancer medicine. Founded in 2015, the company has focused on innovation to improve patient care and speed drug development. Its AI-driven multiomics platform reveals comprehensive molecular profiles of cancer patients, examining the immune system and tumor environment to pinpoint key disease drivers and potential drug targets.
By applying advanced bioanalytics, drawing on an extensive cancer library tailored to specific indications, and operating a next-generation, certified high-complexity laboratory, BostonGene delivers clinically validated insights. These insights propel precision medicine and help move oncology research forward.
About the Stevie Awards
The Stevie Awards encompass multiple programs that recognize outstanding organizational performance worldwide. Categories include Technology Excellence, which honors individuals and organizations advancing technological innovation. Each year, thousands of entries are submitted from over 70 countries, underscoring the Stevies’ reputation as a premier business award.
Frequently Asked Questions
What are the Stevie Awards?
The Stevie Awards are global business honors that recognize excellence across many industries, celebrating both organizational and individual achievements in areas such as technology and healthcare.
Which awards did BostonGene receive?
BostonGene earned one Gold Stevie for its AI-based digital pathology platform and two Silver Stevies for its immune system profiling platform and the Tumor Portrait™ test.
Why is the Gold Stevie significant?
The Gold Stevie is a top honor from the Stevie Awards, recognizing exceptional innovation and achievement within technology-focused categories.
How does BostonGene advance cancer care?
BostonGene uses AI-driven, multiomics technologies to reveal detailed molecular profiles of cancer patients, supporting personalized treatment decisions that can improve patient outcomes.
What sets the Tumor Portrait™ test apart?
The Tumor Portrait™ test identifies actionable mutations and assesses the immune microenvironment, then unifies DNA and RNA results into a single comprehensive report to guide targeted treatment choices.